Single-cell Profiles and Prognostic Impact of Tumor-Infiltrating Lymphocytes Coexpressing CD39, CD103, and PD-1 in Ovarian Cancer
Open Access
- 7 May 2021
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 27 (14) , 4089-4100
Abstract
Purpose: Tumor-infiltrating lymphocytes (TIL) are strongly associated with survival in most cancers; however, the tumor-reactive subset that drives this prognostic effect remains poorly defined. CD39, CD103, and PD-1 have been independently proposed as markers of tumor-reactive CD8+ TIL in various cancers. We evaluated the phenotype, clonality, and prognostic significance of TIL expressing various combinations of these markers in high-grade serous ovarian cancer (HGSC), a malignancy in need of more effective immunotherapeutic approaches. Experimental Design: Expression of CD39, CD103, PD-1, and other immune markers was assessed by high-dimensional flow cytometry, single-cell sequencing, and multiplex immunofluorescence of primary and matched pre/post-chemotherapy HGSC specimens. Results: Coexpression of CD39, CD103, and PD-1 (“triple-positive” phenotype) demarcated subsets of CD8+ TIL and CD4+ regulatory T cells (Treg) with a highly activated/exhausted phenotype. Triple-positive CD8+ TIL exhibited reduced T-cell receptor (TCR) diversity and expressed genes involved in both cytolytic and humoral immunity. Triple-positive Tregs exhibited higher TCR diversity and a tumor-resident phenotype. Triple-positive TIL showed superior prognostic impact relative to TIL expressing other combinations of these markers. TIGIT was uniquely upregulated on triple-positive CD8+ effector cells relative to their CD4+ Treg counterparts. Conclusions: Coexpression of CD39, CD103, and PD-1 demarcates highly activated CD8+ and CD4+ TIL with inferred roles in cytolytic, humoral, and regulatory immune functions. Triple-positive TIL demonstrate exceptional prognostic significance and express compelling targets for combination immunotherapy, including PD-1, CD39, and TIGIT.Keywords
All Related Versions
Funding Information
- BC Cancer Foundation
- Canadian Cancer Society (704435, 706414)
- Canadian Institutes of Health Research (MOP 142436)
- Terry Fox Research Institute (TFRI#1060)
- Cancer Research Society (21324)
- Canada's Networks of Centres of Excellence (FY16/CORE7)
- Paul G. Allen Frontiers Group
- CIHR (429161)
- Michael Smith Health Research BC (RT-2020-0630)
- MSFHR (16631)
- CIHR (MFE-158087)
- CIHR (434254)
This publication has 50 references indexed in Scilit:
- Surveillance of the Tumor Mutanome by T Cells during Progression from Primary to Recurrent Ovarian CancerClinical Cancer Research, 2014
- Tumor-Infiltrating Lymphocytes Expressing the Tissue Resident Memory Marker CD103 Are Associated with Increased Survival in High-Grade Serous Ovarian CancerClinical Cancer Research, 2014
- CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in TumorClinical Cancer Research, 2014
- The broad-spectrum antiviral functions of IFIT and IFITM proteinsNature Reviews Immunology, 2012
- CD20+ Tumor-Infiltrating Lymphocytes Have an Atypical CD27− Memory Phenotype and Together with CD8+ T Cells Promote Favorable Prognosis in Ovarian CancerClinical Cancer Research, 2012
- Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysisGynecologic Oncology, 2012
- Profound elevation of CD8+ T cells expressing the intraepithelial lymphocyte marker CD103 (αE/β7 Integrin) in high-grade serous ovarian cancerGynecologic Oncology, 2010
- Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic FactorsPLOS ONE, 2009
- Distinct Profiles of Cytotoxic Granules in Memory CD8 T Cells Correlate with Function, Differentiation Stage, and Antigen ExposureJournal of Virology, 2009
- Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the αEβ7 integrinNature, 1994